Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Akebia Therapeutics, Inc. (AKBA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 8-K Quarterly results
Docs: "Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
05/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights"
03/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights"
08/04/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones"
08/05/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates"
08/10/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
03/10/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights"
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 6, 2019 AKEBIA THERAPEUTICS, INC. Delaware 001-36352 20-8756903 245 First Street Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 871-2098 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement com...",
"Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO 2 VATE Studies and Announces Key Executive Appointments"
08/11/2015 8-K Quarterly results
Docs: "Controlled Equity Offering Sales Agreement, between Akebia Therapeutics, Inc. and Cantor Fitzgerald & Co",
"Opinion of Ropes & Gray LLP",
"Akebia Announces Second Quarter 2015 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy